 OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to stage IV vs other, performance status 0 or 1 vs 2, start of front-line chemotherapy from randomization less than 16 weeks vs at least 16 weeks, gender, and prior taxane therapy yes vs no. Patients are randomized to 1 of 2 treatment arms. 